Our in vivo results are therefore consistent with the in vitro experiments and suggest that not only do ETV1 and ERG promote the formation of larger tumours, but that MET also participates in these effects, notably observed by the reversal of ETV1/ERG‐induced tumour progression by Capmatinib. The gene discussed is ETV1; the disease is neoplasm.